Cullinan therapeutics receives approval to initiate its global phase 1 clinical trial of cln-978 for the treatment of systemic lupus erythematosus

Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of cln-978 for patients with systemic lupus erythematosus

CGEM Ratings Summary

CGEM Quant Ranking